Your browser doesn't support javascript.
loading
A Phase I Trial to Determine the Pharmacokinetics, Psychotropic Effects, and Safety Profile of a Novel Nanoparticle-Based Cannabinoid Spray for Oromucosal Delivery.
Lorenzl, Stefan; Gottwald, Franz; Nistler, Angelika; Brehm, Laura; Grötsch, Renate; Haber, Georg; Bremm, Christian; Weck, Christiane; Trummer, Carina; Brand, Werner.
Afiliação
  • Lorenzl S; Institute of Nursing Science and Practice, Paracelsus Medical University, Salzburg, Austria.
  • Gottwald F; Department of Palliative Care, University Hospital Munich, Ludwig-Maximilians-University, Munich, Germany.
  • Nistler A; Department of Neurology, University Hospital Agatharied, Hausham, Germany.
  • Brehm L; CannaXan GmbH, Warngau, Germany.
  • Grötsch R; Apurano Pharmaceuticals GmbH, Warngau, Germany.
  • Haber G; Apurano Pharmaceuticals GmbH, Warngau, Germany.
  • Bremm C; Gemeinschaftspraxis Dr. Grötsch & Dr. Heimer, Holzkirchen, Germany.
  • Weck C; Department of Neurology, University Hospital Agatharied, Hausham, Germany.
  • Trummer C; Dürnbachstrasse 54a, Schliersee, Germany.
  • Brand W; Institute of Nursing Science and Practice, Paracelsus Medical University, Salzburg, Austria.
Med Cannabis Cannabinoids ; 5(1): 9-19, 2022.
Article em En | MEDLINE | ID: mdl-35224436
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2022 Tipo de documento: Article